Skip to main content

Table 1 Characteristics of the patients according to minimal residual disease (MRD) in TP1 and TP2

From: Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia

Characteristics

MRD after the first induction course (n = 524)

MRD before start of consolidation (n = 467)

 

All

 < 0.1%

 ≥ 0.1%

P

All

 < 0.1%

 ≥ 0.1%

P

Sex, n (%)

   

0.453

   

0.164

 Male

313 (59.7)

200 (61.0)

113 (57.7)

 

277 (59.3)

243 (60.6)

34 (51.5)

 

 Female

211 (40.3)

128 (39.0)

83 (42.3)

 

190 (40.7)

158 (39.4)

32 (48.5)

 

Age, n (%)

   

0.677

   

0.075

  < 10 years

412 (78.6)

256 (78.0)

156 (79.6)

 

364 (77.9)

307 (76.6)

57 (86.4)

 

  ≥ 10 years

112 (21.4)

72 (22.0)

40 (20.4)

 

103 (22.1)

94 (23.4)

9 (13.6)

 

WBC at diagnosis, n (%)

   

0.175

   

0.028

 ≥ 50 × 109/L

158 (30.2)

92 (28.0)

66 (33.7)

 

144 (30.8)

116 (28.9)

28 (42.4)

 

  < 50 × 109/L

366 (69.8)

236 (72.0)

130 (66.3)

 

323 (69.2)

285 (71.1)

38 (57.6)

 

 CNSL at diagnosis, n (%)

18 (3.6)

9 (2.7)

9 (4.6)

0.261

17 (3.6)

12 (3.0)

5 (7.6)

0.020

FAB classification, n (%)

   

0.910

   

0.541

 M7

41 (7.8)

26 (7.9)

15 (7.7)

 

34 (7.3)

28 (7.0)

6 (9.1)

 

 Non-M7

483 (92.2)

302 (92.1)

181 (92.3)

 

433 (92.7)

373 (93.0)

60 (90.9)

 

Genetic subgroups, n (%)

 RUNX1-RUNX1T1

139 (26.5)

94 (28.7)

45 (23.0)

0.153

127 (27.2)

114 (28.4)

9 (13.6)

0.011

 CBFB-MYH11

35 (6.7)

24 (7.3)

11 (5.6)

0.439

33 (7.1)

29 (7.2)

4 (6.1)

0.929

 KMT2A-r excluded MLLT3-KMT2A

56 (10.7)

33 (10.1)

23 (11.7)

0.548

49 (10.5)

40 (10.0)

9 (13.6)

0.368

 MLLT3-KMT2A

42 (8.0)

26 (7.9)

16 (8.2)

0.923

36 (7.7)

32 (8.0)

4 (6.1)

0.919

 FLT3-ITD mutation

51 (9.7)

28 (8.5)

23 (11.7)

0.232

43 (9.2)

36 (9.0)

7 (10.6)

0.324

Risk stratification according to

C-HUANAN-AML 15 criteria, n (%)

   

0.000

   

0.000

 HR

114 (21.8)

52 (15.9)

62 (31.6)

 

96 (20.6)

67 (16.7)

29 (43.9)

 

 Non-HR

410 (78.2)

276 (84.1)

134 (68.4)

 

371 (79.4)

334 (83.3)

37 (56.1)

 

Risk stratification according to

2017 ELN criteria, n (%)

   

0.156

   

0.135

 HR

191 (36.3)

112 (34.1)

79 (40.3)

 

167 (35.8)

138 (34.4)

29 (43.9)

 

 Non-HR

333 (63.7)

216 (65.9)

117 (59.7)

 

300 (64.2)

263 (65.6)

37 (56.1)

 

HSCT in primary therapy

   

0.057

   

0.009

 Yes

156 (29.8)

88 (26.8)

68 (34.7)

 

135 (28.9)

107 (26.7)

28 (42.4)

 

 No

368 (70.2)

240 (73.2)

128 (65.3)

 

332 (71.1)

294 (73.3)

38 (57.6)

 
  1. TP1 on days 28–35 after the first induction course, TP2 at the end of the second induction course (before start of consolidation), N number, WBC white blood cell count, FAB French-American-British, FLT3-ITD FLT3 internal tandem duplication, CNSL central nervous system leukemia, HR high risk, ELN European LeukemiaNet, HSCT hematopoietic stem cell transplantation
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us